A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
A phase 1/2 trial of Sacituzumab tirumotecan, Fluorouracil, FLOT in colorectal cancer and pancreatic ductal adenocarcinoma, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) is a phase 1/2 interventional study registered as NCT06428409 by Merck Sharp & Dohme LLC, with 220 participants planned, started 2024-06-20 and due to reach its primary completion in 2029-10-16. Interventions recorded: Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures. Conditions listed: Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Shares Fluorouracil (5-FU), Sacituzumab tirumotecan, Merck & Co. (MSD), Pembrolizumab.
- TrialEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Shares Fluorouracil (5-FU), Cisplatin, Merck & Co. (MSD), Pembrolizumab.
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc
Shares Sacituzumab tirumotecan, Cisplatin, Merck & Co. (MSD), Pembrolizumab.
- TrialA Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan
Shares Sacituzumab tirumotecan, Cisplatin, Merck & Co. (MSD), Pembrolizumab.
- TrialPembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
Shares Sacituzumab tirumotecan, Cisplatin, Merck & Co. (MSD), Pembrolizumab.
- TrialBOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Colorectal cancer.
- TrialA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm
Shares Sacituzumab tirumotecan, Cisplatin, Merck & Co. (MSD), Pembrolizumab.
- TrialEfficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Shares Cisplatin, Merck & Co. (MSD), Pembrolizumab, Pancreatic ductal adenocarcinoma.